Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-978 in Active, Moderate to Severe Sjogren's Disease
NCT07041099Phase 1Recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of CLN-978 in Sjogren's syndrome (2 arms), sponsored by Cullinan Therapeutics. Primary endpoint: Safety and Tolerability at 48 weeks. Started Oct 2025; status: recruiting.
02
Drugs
CLN-978
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT07041099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041099.